Glaukos (GKOS)
NYSE:GKOS
Want to see GKOS full AI Analyst Report?
GKOS Stock Chart & Stats
$124.79
$1.50(0.96%)
At close: 4:00 PM EST
$124.79
$1.50(0.96%)
Day’s Range― - ―
52-Week Range$73.16 - $130.23
Previous CloseN/A
Volume137.72K
Average Volume (3M)693.35K
Market Cap
$7.03B
Enterprise Value$7.30B
Total Cash (Recent Filing)$278.76M
Total Debt (Recent Filing)$139.64M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Apr 29, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding58,078,810
10 Day Avg. Volume581,790
30 Day Avg. Volume693,347
Financial Highlights & Ratios
PEG Ratio-1.87
Price to Book (P/B)9.84
Price to Sales (P/S)12.73
P/FCF Ratio-119.57
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue14.38
Enterprise Value/Gross Profit18.05
Enterprise Value/Ebitda-49.89
Forecast
1Y Price Target
$132.50Price Target Upside6.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$613.33M
Bulls Say, Bears Say
Bulls Say
Diversified Growth PipelineMultiple growth drivers including corneal products, iDose, and other ophthalmic initiatives reduce single-product execution risk and increase chances for upside to estimates.
Epioxa CommercializationInitial Epioxa rollout is progressing with system placements across a large portion of the U.S. and encouraging payer conversations, supporting adoption and potential corneal business growth.
Financial Strength And MarginsHigh gross margins combined with a substantial cash and investment position enable continued investment behind commercialization and pipeline expansion without immediate financing pressure.
Bears Say
Near-term Sales Volatility From Product TransitionTransition from the legacy corneal therapy to the new system and planned patient stockpiling ahead of the launch are likely to depress corneal health sales temporarily, creating short-term revenue swings.
Regulatory And Reimbursement UncertaintyPotential Medicare local coverage decisions and updated implant label requirements that narrow eligible patients or impose additional clinical steps could restrict procedural uptake and complicate reimbursement.
Valuation RiskStock trades at a notable premium to peers, which could lead to downside if sales growth or product adoption fails to meet elevated expectations.
Glaukos News
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $73.16 and its highest was $130.23 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $7.03B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Apr 29, 2026 which is in 10 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Feb 17, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.196 by -$0.084.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.28.
How many shares outstanding does Glaukos have?
Glaukos has 58,078,810 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.196. Following the earnings report the stock price went up 13.466%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Glaukos Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$132.50 (6.18% Upside)
$132.50 (6.18% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 702.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.25%
12-Months-Change
Fundamentals
Return on Equity
-25.41%
Trailing 12-Months
Asset Growth
-10.21%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
GKOS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported multiple substantial positive developments: record Q4 and FY2025 revenue, strong iDose TR adoption and revenue (~$136M in 2025), FDA approval and active commercial launch progress for Epioxa, tangible early payer engagement and site deployments, and continued pipeline momentum across several programs. Challenges and near-term headwinds were acknowledged — including Q4 iDose sequential dynamics, expected transition volatility from Photrexa to Epioxa (temporary misc J-code impacts and prior-authorization delays), international competitive trialing, and higher OpEx to support launches. Overall, the positives (record results, robust product momentum, successful approval and launch activities, and clear guidance) materially outweigh the manageable and largely execution/timing-related lowlights.View all GKOS earnings summariesGKOS Stock 12 Month Forecast
Average Price Target
$132.50
▲(6.18% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
3.95% Insiders
35.20% Mutual Funds
0.05% Other Institutional Investors
37.31% Public Companies and
Individual Investors